skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

New and improved strategies for the treatment of gout

Review

(2871) Views  (1155) Full article downloads

Authors: Natalie Dubchak, Gerald F Falasca

Published Date November 2010 Volume 2010:3 Pages 145 - 166
DOI: http://dx.doi.org/10.2147/IJNRD.S6048

Natalie Dubchak, Gerald F Falasca
Division of Rheumatology, Cooper University Hospital, UMDNJ – Robert Wood Johnson Medical School at Camden, Camden, NJ, USA

Abstract: The Western world appears to be in the midst of the third great gout epidemic of all time. In this century, gout is increasing in prevalence despite an increased understanding of its risk factors and pathophysiology, and the availability of reasonably effective treatment. The main cultural factors responsible for this appear to be diet, obesity, ethanol use and medications. Excess fructose consumption is a newly recognized modifiable risk factor. The debate has been renewed concerning hyperuricemia as an independent risk factor for renal insufficiency and cardiovascular disease. Prevention is still rooted in lifestyle choices. Existing treatments have proven to be unsatisfactory in many patients with comorbidities. New treatments are available today and on the horizon for tomorrow, which offer a better quality of life for gout sufferers. These include febuxostat, a nonpurine inhibitor of xanthine oxidase with a potentially better combination of efficacy and safety than allopurinol, and investigational inhibitors of URAT-1, an anion exchanger in the proximal tubule that is critical for uric acid homeostasis. New abortive treatments include interleukin-1 antagonists that can cut short the acute attack in 1 to 2 days in persons who cannot take nonsteroidal anti-inflammatory drugs, colchicine or corticosteroids. Lastly, newer formulations of uricase have the ability to dissolve destructive tophi over weeks or months in patients who cannot use currently available hypouricemic agents. Diagnostically, ultrasound and magnetic resonance imaging offer advanced ways to diagnose gout noninvasively, and just as importantly, a way to follow the progress of tophus dissolution. The close association of hyperuricemia with metabolic syndrome, hypertension and renal insufficiency ensures that nephrologists will see increasing numbers of gout-afflicted patients.

Keywords: hyperuricemia, metabolic syndrome, tophi, colchicine, febuxostat, allopurinol






Readers of this article also read:

Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction
Manifestation of renal disease in obesity: pathophysiology of obesity-related dysfunction of the kidney
Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
Effect of amlodipine, a calcium channel antagonist, on gonadal steroid of male wistar albino rats
New standards in hypertension and cardiovascular risk management: focus on telmisartan
Gout disease-specific quality of life and the association with gout characteristics
Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment
Update on the diagnosis and management of acute kidney injury
Effect of angiotensin II blockade on central blood pressure and arterial stiffness in subjects with hypertension
The epidemiology and treatment of gout
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio